STROHealthcare · BiotechnologyThe 14 Wall Street analysts covering Sutro Biopharma, Inc. hold a median 12-month price target of $50 — +137.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Sutro Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (84): Sales and profits are climbing, and climbing faster than before.
Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on STRO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +137.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Aug 2026 | Citizens | Maintains | Market Outperform | $41 → $34 |
| 13 Aug 2026 | Wedbush | Reiterates | Outperform | $60 |
| 11 June 2026 | Truist Securities | Assumes | Buy | $50 |
| 28 May 2026 | Barclays | Initiates | Overweight | — |
| 15 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 May 2026 | Leerink Partners | Maintains | Outperform | — |
| 15 May 2026 | Wedbush | Upgrade | Outperform | — |
| 30 Apr 2026 | Mizuho | Initiates | Outperform | — |
| 23 Apr 2026 | Citizens | Maintains | Market Outperform | — |
| 17 Apr 2026 | Citizens | Maintains | Market Outperform | — |
| 7 Apr 2026 | Leerink Partners | Initiates | Outperform | — |
| 25 Mar 2026 | Deutsche Bank | Maintains | Buy | — |
| 24 Mar 2026 | HC Wainwright & Co. | Upgrade | Buy | — |
| 24 Mar 2026 | Wells Fargo | Upgrade | Overweight | — |
| 20 Jan 2026 | Citizens | Upgrade | Market Outperform | — |
| 22 Dec 2025 | HC Wainwright & Co. | Maintains | Neutral | — |
| 12 Aug 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 16 June 2025 | Piper Sandler | Upgrade | Overweight | — |
| 19 May 2025 | B of A Securities | Maintains | Underperform | — |
| 29 Apr 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. STRO appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 18% of US stocks
Cheaper than 96% of US stocks
Cheaper than 69% of US stocks
Higher than 2% of US stocks
Higher than 22% of US stocks
Higher than 9% of US stocks
Higher than 30% of US stocks
Higher than 97% of US stocks
Higher than 12% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Sutro Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Sutro Biopharma shares are trading lower on Wednesday, according to the report, as the company faces challenges following its recent update on the STRO-004 Phase 1 study.
Why it matters — A STRO watcher would care because the company is contending with challenges stemming from its STRO-004 Phase 1 study update, which is weighing on the stock.
Sutro Biopharma reported its second quarter 2026 financial results and provided an early update on its STRO-004 Phase 1 study, citing encouraging clinical activity including confirmed and ongoing unconfirmed partial responses with favorable tolerability and pharmacokinetics. The company reported $164.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026, expected to support operations into at least the second quarter of 2028, and noted that STRO-006 is on track to enter the clinic in Q3 2026 while a second dual-payload program under the Astellas collaboration is expected to enter the clinic in the second half of 2026.
Why it matters — The early positive clinical data for STRO-004, on-track progress of STRO-006 and the Astellas collaboration program, and a cash runway through at least Q2 2028 give STRO watchers insight into the company's pipeline momentum and financial stability.
The 14 Wall Street analysts covering Sutro Biopharma, Inc. have a median 12-month price target of $50, with estimates ranging from $10 to $61. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Sutro Biopharma, Inc., 13 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Sutro Biopharma, Inc. 75 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Sutro Biopharma, Inc. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (84 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +137.6% from the last close, and Ticker Nerd's factor model ranks Sutro Biopharma, Inc. 75 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Sutro Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STRO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $61 over the next 12 months.
Sutro Biopharma, Inc. returned +147.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Sutro Biopharma, Inc. is a clinical-stage biotechnology company specializing in oncology, headquartered in South San Francisco, California.
The most recent item we track (Benzinga, 12 Aug 2026): "Why is Sutro Biopharma Stock Falling On Wednesday?". Sutro Biopharma shares are trading lower on Wednesday, according to the report, as the company faces challenges following its recent update on the STRO-004 Phase 1 study.
Sutro Biopharma, Inc. is a clinical-stage biotechnology company specializing in oncology, headquartered in South San Francisco, California. The company focuses on discovering, developing, and manufacturing next-generation antibody-drug conjugates (ADCs) using its proprietary, integrated cell-free protein synthesis platform XpressCF and site-specific conjugation platform XpressCF+. These technologies enable precise design of single- and dual-payload ADCs intended to optimize antibody, linker, and payload components for improved targeting and drug delivery in cancer treatment. Sutro Biopharma’s current pipeline centers on its lead candidate luveltamab tazevibuline (STRO-002, or luvelta), an ADC directed against folate receptor alpha for tumors such as ovarian cancer, as well as in certain pediatric leukemias. The company also develops STRO-001, targeting CD74 in B-cell malignancies, and earlier-stage homogeneous ADCs such as STRO-003 and STRO-004 directed at solid tumor targets including ROR1 and tissue factor. Through this focused ADC platform, Sutro Biopharma plays a specialized role in the biopharmaceutical market for targeted cancer therapeutics.
CEO Ms. Jane Chung R.Ph. · 128 employees · United States · https://www.sutrobio.com